Teva Struggles To Sell 2014 Guidance, Blue-Sky Estimates For NTE Program
Executive Summary
The Israeli generics giant unveiled two sets of 2014 guidance, allowing for different levels of competition for Copaxone. But Wall Street sees the company slowing the pace of cost-cutting and providing overly optimistic revenue estimates for new therapeutic entities.